Basit öğe kaydını göster

dc.contributor.authorVolkan, Burcu
dc.contributor.authorÖktem, Sedat
dc.contributor.authorBoran, Perran
dc.contributor.authorTokuç, Gülnür
dc.date.accessioned2021-06-16T11:48:14Z
dc.date.available2021-06-16T11:48:14Z
dc.date.issued2020en_US
dc.identifier.citationVolkan, B., Öktem, S., Boran, P. ve Tokuç, G. (2020). Comparison of the treatment efficacy of montelukast and zafirlukast in children with asthma. Haydarpaşa Numune Medical Journal, 60(4), 329-334. https://dx.doi.org/10.14744/hnhj.2019.30164en_US
dc.identifier.issn2630-5720
dc.identifier.urihttps://dx.doi.org/10.14744/hnhj.2019.30164
dc.identifier.urihttps://hdl.handle.net/20.500.12511/7202
dc.description.abstractIntroduction: Asthma is one of the most common respiratory disorders in clinical practice, affecting up to 13% of people worldwide. Leukotriene antagonists have long been used in the treatment of asthma. This study was conducted to compare the effectiveness of the montelukast and zafirlukast treatment in children diagnosed with asthma. Methods: Sixty-one patients diagnosed with asthma in the age group of 6-14 years were included in the study. Patients were consecutively divided into 2 groups, and the first group was given 5 mg of montelukast before sleep and the second group received 10 mg/day of zafirlukast in two doses. The patients were followed up monthly for 6 months. Short acting beta agonist and inhaled corticosteroid use, daytime symptoms, night awakenings, admission to the emergency department andFEV1 value were compared before and after the treatment and between two groups. Results: Significant improvement was observed in both groups during post-treatment period when compared to the pre-treatment period in terms of the short acting beta agonist and inhaled corticosteroid use, daytime symptoms, night awakenings, mean FEV I. However, no statistical difference was determined between two groups. Discussion and Conclusion: It was found that monteluksat and zafirlukast were effective in asthma treatment and there was no difference between their effects.en_US
dc.language.isoengen_US
dc.publisherHaydarpaşa Numune Medicalen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAttribution-NonCommercial 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectAsthmaen_US
dc.subjectMontelukasten_US
dc.subjectZafirlukasten_US
dc.titleComparison of the treatment efficacy of montelukast and zafirlukast in children with asthmaen_US
dc.typearticleen_US
dc.relation.ispartofHaydarpaşa Numune Medical Journalen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalıen_US
dc.authorid0000-0002-7950-2067en_US
dc.identifier.volume60en_US
dc.identifier.issue4en_US
dc.identifier.startpage329en_US
dc.identifier.endpage334en_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.14744/hnhj.2019.30164en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster

info:eu-repo/semantics/openAccess
Aksi belirtilmediği sürece bu öğenin lisansı: info:eu-repo/semantics/openAccess